NURS 6521 ADVANCED PHARMACOLOGY FINAL EXAM
2026/2027 | Comprehensive APRN Prescribing | 100% Verified
| Latest Update | Graded A | Pass Guaranteed
Section 1: Pharmacokinetics & Pharmacodynamics (Q1-15)
Q1. A 68-year-old male with liver cirrhosis is prescribed a drug that undergoes extensive
Phase I CYP450 metabolism. The APRN expects which pharmacokinetic alteration?
A. Increased bioavailability due to decreased first-pass metabolism
B. Decreased volume of distribution due to increased albumin
C. Increased clearance due to hepatic enzyme induction
D. Shortened half-life due to increased plasma protein binding
Correct Answer: A. Increased bioavailability due to decreased first-pass metabolism
[CORRECT]
Rationale: In liver cirrhosis, hepatocellular damage reduces first-pass metabolism,
increasing bioavailability of drugs with high hepatic extraction. Phase I metabolism is
impaired, while option B is incorrect because cirrhosis causes hypoalbuminemia
(increased free fraction), not increased albumin.
Q2. A patient taking carbamazepine for epilepsy starts rifampin for tuberculosis
prophylaxis. The APRN anticipates which pharmacokinetic interaction?
A. Increased carbamazepine levels due to CYP3A4 inhibition
B. Decreased carbamazepine levels due to CYP450 enzyme induction
C. Increased carbamazepine half-life due to decreased renal clearance
D. No interaction because both drugs use different metabolic pathways
Correct Answer: B. Decreased carbamazepine levels due to CYP450 enzyme induction
[CORRECT]
Rationale: Rifampin is a potent inducer of multiple CYP450 enzymes, accelerating
carbamazepine metabolism and potentially causing subtherapeutic anticonvulsant
levels. The APRN must monitor drug levels and increase the carbamazepine dose
accordingly.
,Q3. A 45-year-old female receives a new medication with a half-life of 8 hours. How
many hours are required to reach approximately 97% of steady-state concentration?
A. 16 hours
B. 24 hours
C. 32 hours
D. 40 hours
Correct Answer: C. 32 hours [CORRECT]
Rationale: Steady-state concentration is achieved after 4-5 half-lives; 4 half-lives (32
hours) yield approximately 94% of steady state, while 5 half-lives yield 97%. The APRN
uses this principle to determine appropriate timing for therapeutic drug monitoring.
Q4. A patient with a CYP2D6 poor metabolizer genotype is prescribed codeine 30 mg
every 4 hours for postoperative pain. What is the clinical consequence?
A. Enhanced analgesia due to increased morphine conversion
B. Therapeutic failure due to inadequate conversion to active morphine
C. Increased risk of respiratory depression from morphine accumulation
D. Prolonged half-life of codeine due to decreased renal clearance
Correct Answer: B. Therapeutic failure due to inadequate conversion to active morphine
[CORRECT]
Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion to morphine for
analgesic effect; poor metabolizers cannot efficiently perform this biotransformation,
resulting in suboptimal pain control. The APRN should select an alternative analgesic
not dependent on CYP2D6 activation.
Q5. A drug has an ED50 of 10 mg and an LD50 of 100 mg. What is the therapeutic
index?
A. 1
B. 10
C. 100
D. 0.1
Correct Answer: B. 10 [CORRECT]
Rationale: The therapeutic index is calculated as LD50 divided by ED50 (100/10 = 10),
indicating a tenfold margin between the effective dose and potentially lethal dose.
,Drugs with narrow therapeutic indices (e.g., digoxin, lithium) require careful monitoring
as small dosing errors can precipitate toxicity.
Q6. A 55-year-old male with heart failure receives a highly protein-bound drug (99%
bound) shortly after starting furosemide. The APRN monitors for which effect?
A. Increased drug effect due to displacement from albumin binding sites
B. Decreased drug effect due to enhanced hepatic metabolism
C. No clinical significance because displacement is transient
D. Decreased volume of distribution requiring dose reduction
Correct Answer: A. Increased drug effect due to displacement from albumin binding
sites [CORRECT]
Rationale: Furosemide can displace highly protein-bound drugs from albumin,
transiently increasing free drug concentration and pharmacologic effect. In heart failure
patients with altered pharmacokinetics, the APRN must monitor for enhanced drug
activity or toxicity when adding displacing agents.
Q7. A patient asks why sublingual nitroglycerin works faster than swallowed
nitroglycerin tablets. The APRN explains which pharmacokinetic principle?
A. Sublingual administration bypasses hepatic first-pass metabolism
B. Oral tablets have higher bioavailability than sublingual formulations
C. Sublingual absorption is slower due to reduced blood flow
D. First-pass metabolism increases sublingual drug concentration
Correct Answer: A. Sublingual administration bypasses hepatic first-pass metabolism
[CORRECT]
Rationale: Sublingual administration allows direct absorption into the systemic
circulation via sublingual veins, bypassing portal circulation and hepatic first-pass
metabolism. This results in rapid onset (1-3 minutes) compared to oral nitroglycerin,
which undergoes extensive presystemic metabolism yielding very low bioavailability.
Q8. A 70-year-old female with renal impairment (CrCl 30 mL/min) receives a drug
primarily eliminated by glomerular filtration. What adjustment is necessary?
A. Increase the dose and lengthen the dosing interval
B. Decrease the dose or lengthen the dosing interval
, C. No adjustment needed because tubular secretion compensates
D. Switch to the intravenous route to improve clearance
Correct Answer: B. Decrease the dose or lengthen the dosing interval [CORRECT]
Rationale: In renal impairment, decreased glomerular filtration reduces drug elimination,
prolonging half-life and increasing risk of accumulation toxicity. The APRN must either
reduce the maintenance dose or extend the dosing interval to prevent toxic plasma
concentrations, following established renal dosing guidelines.
Q9. A partial agonist is prescribed to a patient currently taking a full agonist at the same
receptor. What pharmacodynamic outcome is expected?
A. Additive effect producing greater maximal response
B. Competitive blockade reducing the overall effect
C. No interaction because partial agonists lack affinity
D. Increased receptor downregulation and tolerance
Correct Answer: B. Competitive blockade reducing the overall effect [CORRECT]
Rationale: A partial agonist has lower intrinsic efficacy than a full agonist; when both
occupy the same receptor population, the partial agonist competitively inhibits the full
agonist's maximal effect, producing a net reduction in pharmacologic response. This
principle explains why buprenorphine can precipitate withdrawal in opioid-dependent
patients.
Q10. A 4-year-old child weighing 18 kg requires amoxicillin at 45 mg/kg/day divided
twice daily. What is the individual dose per administration?
A. 202.5 mg
B. 405 mg
C. 810 mg
D. 1620 mg
Correct Answer: B. 405 mg [CORRECT]
Rationale: Total daily dose = 45 mg/kg × 18 kg = 810 mg/day; divided BID = 810/2 = 405
mg per dose. Accurate weight-based pediatric dosing is essential to prevent
2026/2027 | Comprehensive APRN Prescribing | 100% Verified
| Latest Update | Graded A | Pass Guaranteed
Section 1: Pharmacokinetics & Pharmacodynamics (Q1-15)
Q1. A 68-year-old male with liver cirrhosis is prescribed a drug that undergoes extensive
Phase I CYP450 metabolism. The APRN expects which pharmacokinetic alteration?
A. Increased bioavailability due to decreased first-pass metabolism
B. Decreased volume of distribution due to increased albumin
C. Increased clearance due to hepatic enzyme induction
D. Shortened half-life due to increased plasma protein binding
Correct Answer: A. Increased bioavailability due to decreased first-pass metabolism
[CORRECT]
Rationale: In liver cirrhosis, hepatocellular damage reduces first-pass metabolism,
increasing bioavailability of drugs with high hepatic extraction. Phase I metabolism is
impaired, while option B is incorrect because cirrhosis causes hypoalbuminemia
(increased free fraction), not increased albumin.
Q2. A patient taking carbamazepine for epilepsy starts rifampin for tuberculosis
prophylaxis. The APRN anticipates which pharmacokinetic interaction?
A. Increased carbamazepine levels due to CYP3A4 inhibition
B. Decreased carbamazepine levels due to CYP450 enzyme induction
C. Increased carbamazepine half-life due to decreased renal clearance
D. No interaction because both drugs use different metabolic pathways
Correct Answer: B. Decreased carbamazepine levels due to CYP450 enzyme induction
[CORRECT]
Rationale: Rifampin is a potent inducer of multiple CYP450 enzymes, accelerating
carbamazepine metabolism and potentially causing subtherapeutic anticonvulsant
levels. The APRN must monitor drug levels and increase the carbamazepine dose
accordingly.
,Q3. A 45-year-old female receives a new medication with a half-life of 8 hours. How
many hours are required to reach approximately 97% of steady-state concentration?
A. 16 hours
B. 24 hours
C. 32 hours
D. 40 hours
Correct Answer: C. 32 hours [CORRECT]
Rationale: Steady-state concentration is achieved after 4-5 half-lives; 4 half-lives (32
hours) yield approximately 94% of steady state, while 5 half-lives yield 97%. The APRN
uses this principle to determine appropriate timing for therapeutic drug monitoring.
Q4. A patient with a CYP2D6 poor metabolizer genotype is prescribed codeine 30 mg
every 4 hours for postoperative pain. What is the clinical consequence?
A. Enhanced analgesia due to increased morphine conversion
B. Therapeutic failure due to inadequate conversion to active morphine
C. Increased risk of respiratory depression from morphine accumulation
D. Prolonged half-life of codeine due to decreased renal clearance
Correct Answer: B. Therapeutic failure due to inadequate conversion to active morphine
[CORRECT]
Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion to morphine for
analgesic effect; poor metabolizers cannot efficiently perform this biotransformation,
resulting in suboptimal pain control. The APRN should select an alternative analgesic
not dependent on CYP2D6 activation.
Q5. A drug has an ED50 of 10 mg and an LD50 of 100 mg. What is the therapeutic
index?
A. 1
B. 10
C. 100
D. 0.1
Correct Answer: B. 10 [CORRECT]
Rationale: The therapeutic index is calculated as LD50 divided by ED50 (100/10 = 10),
indicating a tenfold margin between the effective dose and potentially lethal dose.
,Drugs with narrow therapeutic indices (e.g., digoxin, lithium) require careful monitoring
as small dosing errors can precipitate toxicity.
Q6. A 55-year-old male with heart failure receives a highly protein-bound drug (99%
bound) shortly after starting furosemide. The APRN monitors for which effect?
A. Increased drug effect due to displacement from albumin binding sites
B. Decreased drug effect due to enhanced hepatic metabolism
C. No clinical significance because displacement is transient
D. Decreased volume of distribution requiring dose reduction
Correct Answer: A. Increased drug effect due to displacement from albumin binding
sites [CORRECT]
Rationale: Furosemide can displace highly protein-bound drugs from albumin,
transiently increasing free drug concentration and pharmacologic effect. In heart failure
patients with altered pharmacokinetics, the APRN must monitor for enhanced drug
activity or toxicity when adding displacing agents.
Q7. A patient asks why sublingual nitroglycerin works faster than swallowed
nitroglycerin tablets. The APRN explains which pharmacokinetic principle?
A. Sublingual administration bypasses hepatic first-pass metabolism
B. Oral tablets have higher bioavailability than sublingual formulations
C. Sublingual absorption is slower due to reduced blood flow
D. First-pass metabolism increases sublingual drug concentration
Correct Answer: A. Sublingual administration bypasses hepatic first-pass metabolism
[CORRECT]
Rationale: Sublingual administration allows direct absorption into the systemic
circulation via sublingual veins, bypassing portal circulation and hepatic first-pass
metabolism. This results in rapid onset (1-3 minutes) compared to oral nitroglycerin,
which undergoes extensive presystemic metabolism yielding very low bioavailability.
Q8. A 70-year-old female with renal impairment (CrCl 30 mL/min) receives a drug
primarily eliminated by glomerular filtration. What adjustment is necessary?
A. Increase the dose and lengthen the dosing interval
B. Decrease the dose or lengthen the dosing interval
, C. No adjustment needed because tubular secretion compensates
D. Switch to the intravenous route to improve clearance
Correct Answer: B. Decrease the dose or lengthen the dosing interval [CORRECT]
Rationale: In renal impairment, decreased glomerular filtration reduces drug elimination,
prolonging half-life and increasing risk of accumulation toxicity. The APRN must either
reduce the maintenance dose or extend the dosing interval to prevent toxic plasma
concentrations, following established renal dosing guidelines.
Q9. A partial agonist is prescribed to a patient currently taking a full agonist at the same
receptor. What pharmacodynamic outcome is expected?
A. Additive effect producing greater maximal response
B. Competitive blockade reducing the overall effect
C. No interaction because partial agonists lack affinity
D. Increased receptor downregulation and tolerance
Correct Answer: B. Competitive blockade reducing the overall effect [CORRECT]
Rationale: A partial agonist has lower intrinsic efficacy than a full agonist; when both
occupy the same receptor population, the partial agonist competitively inhibits the full
agonist's maximal effect, producing a net reduction in pharmacologic response. This
principle explains why buprenorphine can precipitate withdrawal in opioid-dependent
patients.
Q10. A 4-year-old child weighing 18 kg requires amoxicillin at 45 mg/kg/day divided
twice daily. What is the individual dose per administration?
A. 202.5 mg
B. 405 mg
C. 810 mg
D. 1620 mg
Correct Answer: B. 405 mg [CORRECT]
Rationale: Total daily dose = 45 mg/kg × 18 kg = 810 mg/day; divided BID = 810/2 = 405
mg per dose. Accurate weight-based pediatric dosing is essential to prevent
